Skip to main content
GALT
NASDAQ Life Sciences

Director Harold Shlevin files intent to sell $1.84M in GALT shares

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$3.785
Mkt Cap
$244.054M
52W Low
$1.07
52W High
$7.13
52W Position info
254% above low
Off High info
47% below high
Rel. Volume info
0.3× avg
Market data snapshot near publication time

GALT has more than doubled off its 52-week low of $1.07 on light trading volume (0.3× avg).

Summary

Director Harold Shlevin filed a Form 144 indicating intent to sell 441,500 shares of Galectin Therapeutics, valued at approximately $1.84 million, following previous sales totaling $1.40 million in the last three months.


Key Events · Ownership and Investor Activity · GALT

  • Director Files Intent to Sell

    Director Harold Shlevin has filed a Form 144, indicating his intent to sell 441,500 shares of common stock.

  • Significant Proposed Sale Value

    The proposed sale is valued at approximately $1,836,640.00, representing a substantial transaction for an insider.

  • Pattern of Recent Sales

    This proposed sale follows previous dispositions by Mr. Shlevin, who sold 228,706 shares for $1,395,405.21 in the past three months.


Analysis · GALT · Life Sciences

This Form 144 filing signals a significant intent to sell by Director Harold Shlevin, with the proposed transaction valued at $1.84 million. This amount is notable relative to the company's market capitalization. The filing also reveals that Mr. Shlevin has already sold an additional $1.40 million worth of shares in the preceding three months, suggesting a sustained pattern of reducing his stake. While the sale is likely pre-planned given the adoption date, the cumulative value of these dispositions could be perceived negatively by investors as it represents a substantial reduction in insider ownership.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, GALT was trading at $3.79 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $244.1M. The 52-week trading range was $1.07 to $7.13. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

GALT - Latest Insights

GALT
Nov 16, 2026, 8:00 AM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $3.10
Real-time Price: $2.96 info
Change: -$0.1384 (-4%) info
Market Cap: $293.547M info
GALT
Nov 16, 2026, 7:50 AM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $3.10
Real-time Price: $2.96 info
Change: -$0.1384 (-4%) info
Market Cap: $293.547M info
GALT
Oct 13, 2026, 8:00 AM EDT
Filing Type: DEF 14A
Importance Score:
7
Price at Filing: $3.94
Real-time Price: $2.96 info
Change: -$0.9784 (-25%) info
Market Cap: $293.547M info
GALT
Oct 02, 2026, 3:53 PM EDT
Filing Type: PRE 14A
Importance Score:
7
Price at Filing: $3.92
Real-time Price: $2.96 info
Change: -$0.9534 (-24%) info
Market Cap: $293.547M info
GALT
Aug 14, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $3.45
Real-time Price: $2.96 info
Change: -$0.4884 (-14%) info
Market Cap: $293.547M info